76 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
tax treaty between the United States and such holder’s country of residence) on the net gain derived from the disposition, which may be offset
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
the disposition, which may be offset by certain U.S.-source capital losses of the Non- U.S. Holder, if any; or
our common stock constitutes a U.S. real property
424B5
pal7vnm1i8e9g y4kjp0
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
wk7qanvgh1
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
19qz6iwbhni4cixe
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
424B5
1oyyj
30 Mar 22
Prospectus supplement for primary offering
5:21pm